Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 3/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.43 |
| ▸ | ITGAV | P06756 | 3/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31352928 | 0.95 | KRAS (0.48) | HSP90AB1KRASKLKB1CACNA1BKDM4A | |
| SCHEMBL31328348 | 0.88 | TPSAB1 (0.43) | KRASITGB3ITGAVITGB5ITGA2B | |
| SCHEMBL24739372 | 0.87 | PIN1 (0.46) | HSP90AB1KRASITGB3ITGAVITGB5 | |
| SCHEMBL29666828 | 0.85 | HDAC3 (0.42) | KRASKLKB1 | |
| SCHEMBL29568658 | 0.83 | GHSR (0.42) | KRASITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL29568807 | 0.83 | GHSR (0.42) | KRASITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL29569694 | 0.83 | GHSR (0.42) | KRASITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL12794626 | 0.83 | KRAS (0.48) | KRASKDM4A | |
| SCHEMBL278805 | 0.82 | ITGB3 (0.46) | KRASITGB3ITGAVITGB5ITGA2B | |
| SCHEMBL29924950 | 0.82 | FURIN (0.43) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028374-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | FILAMON LTD (AU) | 2026-01-29 | — | — | US | disclosed |
| WO-2025050169-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | FILAMON PTY LTD (AU) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028374-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | EGFR, ERBB2, ERBB3 | HSP90AB1 3092/4885KRAS 3413/4885ITGB3 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.